Building on these advancements, the scaffold was further optimized by replacing the N-terminal H-Glu-Ala-Tyr-Gly sequence with γ-D-Glu-PEG3 to yield DOTA-CCK-66, which exhibited increased metabolic stability and urinary clearance while maintaining excellent tumor targeting and imaging performance 4. This evidence concerns the gene CCK and neoplasm.